ArticleNeuropharmacology2017
Amylin receptor activation in the ventral tegmental area reduces motivated ingestive behavior.
Article in Neuropharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 58 citations in OpenAlex.
- Amylin: A Multi-Functional Pancreatic Hormone-A Review.Diabetes, obesity & metabolism · 2026Review
- Not only gut feelings: pancreatic hormone, amylin, controls emotionality and sociability, in a sex divergent manner.Translational psychiatry · 2026Article
- Brain Amylin Signaling, Feeding, and Reward.Comprehensive Physiology · 2026Review
- The story of amylin: from physiology to therapy.Nature metabolism · 2026Review
- Central pramlintide administration potently suppresses operant responding for sucrose and locomotor activity in male rats.Physiology & behavior · 2025Article
- Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue.Journal of medicinal chemistry · 2025Article
- From the pancreas to the amygdala: New brain area critical for ingestive and motivated behavior control exerted by amylin.iScience · 2025Article
- Ventral tegmental area amylin / calcitonin receptor signaling suppresses feeding and weight gain in female rats.Neuroscience research · 2025Article
- GLP-1 Receptor Agonists: Promising Therapeutic Targets for Alcohol Use Disorder.Endocrinology · 2025Review
- Fluid transitions.Neuropharmacology · 2024Review
- Article
- Amylin Modulates a Ventral Tegmental Area-to-Medial Prefrontal Cortex Circuit to Suppress Food Intake and Impulsive Food-Directed Behavior.Biological psychiatry · 2024Article
- The alpha-7 nicotinic acetylcholine receptor agonist PHA-543613 reduces food intake in male rats.Pharmacology, biochemistry, and behavior · 2024Article
- Metabolic hormone action in the VTA: Reward-directed behavior and mechanistic insights.Physiology & behavior · 2023Review
- Chronic salmon calcitonin exerts an antidepressant effectFrontiers in molecular neuroscience · 2023Article
- Macronutrient intake: Hormonal controls, pathological states, and methodological considerations.Appetite · 2023Review
- The therapeutic potential of glucagon-like peptide-1 for persons with addictions based on findings from preclinical and clinical studies.Frontiers in pharmacology · 2023Review
- The alpha-7 nicotinic acetylcholine receptor agonist GTS-21 does not affect food intake in rats.Pharmacology, biochemistry, and behavior · 2022Article
- Actions of feeding-related peptides on the mesolimbic dopamine system in regulation of natural and drug rewards.Addiction neuroscience · 2022Article
- Obesity - A Matter of Motivation?Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
Amylin is produced in the pancreas and the brain, and acts centrally to reduce feeding and body weight. Recent data show that amylin can act in the ventral tegmental area (VTA) to reduce palatable food intake and promote negative energy balance, but the behavioral mechanisms by which these effects occur are not fully understood. The ability of VTA amylin signaling to reduce intake of specific palatable macronutrients (fat or carbohydrate) was tested in rats in several paradigms, including one-bottle acceptance tests, two-bottle choice tests, and a free-choice diet. Data show that VTA amylin receptor activation with the amylin receptor agonist salmon calcitonin (sCT) preferentially and potently reduces intake of fat, with more variable suppression of sucrose intake. Intake of a non-nutritive sweetener is also decreased by intra-VTA administration of sCT. As several feeding-related signals that act in the mesolimbic system also impact motivated behaviors besides feeding, we tested the hypothesis that the suppressive effects of amylin signaling in the VTA extend to other motivationally relevant stimuli. Results show that intra-VTA sCT reduces water intake in response to central administration of the dipsogenic peptide angiotensin II, but has no effect on ad libitum water intake in the absence of food. Importantly, open field and social interaction studies show that VTA amylin signaling does not produce anxiety-like behaviors. Collectively, these findings reveal a novel ability of VTA amylin receptor activation to alter palatable macronutrient intake, and also demonstrate a broader role of VTA amylin signaling for the control of motivated ingestive behaviors beyond feeding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.